



**IPSOGEN**  
CANCER PROFILER

# PRESS RELEASE

## MAY 29, 2012 ANNUAL SHAREHOLDERS' GENERAL MEETING

**Marseille, May 24, 2012** - IPSOGEN S.A. (Alternext: ALIPS, ISIN: FR0010626028), a pioneer and key player in the development and marketing of molecular diagnostic tests for cancer, recalls that an annual general meeting of shareholders will be held on May, 29, 2012 in Marseille, France.

During this meeting the Board of Directors will present its management report for the financial year ended December 31, 2011 to the shareholders. The 2011 financial year was marked by the successful acquisition by QIAGEN of a large majority stake in IPSOGEN capital. Today, QIAGEN holds, pursuant to its public offer on IPSOGEN, 89.30% of share capital and 86.47% of voting rights of the Company.

2011 year is also remarkable because of the very dynamic growth in the sales of kits: +23% compared to year 2010. Licenses revenue has decreased by 11% compared to the year 2010. This decrease is due to the existence of non-recurring items booked in 2010 following the settlement of the litigation with the company BRL and the execution of new JAK2 V617F sub-licensing agreements which have generated "look-back" royalties. If the impact of these "one-time events" is neutralized, licenses revenue would have increased by +8% over 2010 year.

Besides, global revenue variation (kits+licenses) between 2010 and 2011 would be +19% instead of +14%.

Research expenditure remained at a high level and the Company continues to benefit from a significant amount of research tax credit. Including government funding for research expenditure, IPSOGEN's operating income totalled €10.1 million over the full year in 2011.

Besides, the year 2011 was significantly impacted by one-time events. The expenses and charges related to these events amount to €5.4 million, of which €4.8 million were recorded during the second half of the year. Excluding these non-recurring events, the net result for the year 2011 would have been close to break-even.

As indicated in the March 21, 2012 press release presenting 2011 annual results, a €2.6 million provision has been booked in the 2011 financial statements in regards to a risk of additional royalty payments. The Board of Directors, on the basis of the Audit Committee's recommendation, has now reassessed the underlying risks and found that such a provision was no longer required and, as a consequence, has decided that such provision shall be released in the 2012 accounts.



**IPSOGEN**  
CANCER PROFILER

# PRESS RELEASE

## About IPSOGEN

*IPSOGEN, "Cancer Profiler," develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with blood cancer, IPSOGEN is also targeting breast cancer. Its goal will be to provide diagnostic information that remained unavailable until now. IPSOGEN is, since July 2011, a subsidiary of the QIAGEN group.*

*As of December 31, 2011, IPSOGEN employed 72 people. Its headquarters are located in Marseilles, France.*

*For further information, visit [www.ipsogen.com](http://www.ipsogen.com).*

## Contacts

---

### IPSOGEN

#### Vincent Fert

CEO

Tel: + 33 (0)4 9129 3090

[fert@ipsogen.com](mailto:fert@ipsogen.com)

#### ATCG Press

Marielle Bricman

Tel: + 33 (0)4 9125 0785

[ipsogen@atcg-partners.com](mailto:ipsogen@atcg-partners.com)

**ALIPS**  
**LISTED**  
**NYSE**  
**ALTERNEXT**

**General shareholders'  
meeting:**

**29/05/2012, in  
Marseilles**

**Revenue for the first-  
half of 2012:**

**06/09/2012, before  
market**